N/A N=56 Opportunities and Limits to Deprescribing in Nursing Homes:Quality Circle Deprescribing Module
Polypharmacy · Inappropriate Prescribing
Primary: Percentage of Potentially Inappropriate Galenic Units — 24; 23 percent — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=320 Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.
Hepatobiliary Disorders · Non-alcoholic Steatohepatitis
Primary: Percentage of Participants With Non- Alcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis After 72 Weeks (Yes/No) — 40.4; 35.6; 58.9; 17.2…
Phase 2 N=33 Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP
Adult Idiopathic Generalized Osteoporosis
Primary: Percent Change in Lumbar Spine Areal BMD by DXA — 5.2 percentage of change
Phase 2 N=26 Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T
HIV
Primary: Treatment-emergent Adverse Events — 3; 6; 11; 3 participants
Phase 3 N=1,351 Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis
Ulcerative Colitis
Primary: Induction Study: Percentage of Participants Who Achieved Endoscopy/Bleeding/Stool Frequency (EBS) Remission at Week 10 — 26.1; 19.1; 15.3; 11.5 percentage of…
Phase 1 N=46 Effect of Food on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Adults
Healthy Volunteer
Primary: Maximum Observed Plasma Concentration (Cmax) of Apremilast — 339.86; 333.85 ng/mL
Phase 3 N=95 Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)
Dermatomyositis
Primary: Measure the Number of Patients Who Had an Increase of ≥20 Points on the Total Improvement Score (TIS) — 21; 37 Participants
Phase 4 N=18 Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU)
Urticaria Chronic
Primary: Time to 50% Decline in Clinical Symptoms Measured by the Urticaria Activity Score Seven Day(UAS7) — 23; 12 days
Phase 2 N=535 Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention
Myocardial Infarction · Acute Coronary Syndromes · Unstable Angina
Primary: The Composite Endpoint of Death, Periprocedural Myonecrosis (PPM), Urgent Target Vessel Revascularization (uTVR) or Major Bleeding — 69; 60; 48 Participants
Phase 2 N=70 Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial
Chronic Kidney Disease
Primary: Mean Percentage Change in Endothelium-dependent Flow-mediated Vasodilation (FMD) Over 12 Weeks — 1.1; 0.3 Percentage change
N/A N=16 The Effects of Immunotherapy in the Nose
Rhinitis, Allergic, Seasonal
Primary: The Total Number of Differentially Expressed Transcripts. — 119; 49 transcripts
Phase 2 N=15 Role of Mirtazapine in Ameliorating Sleep Disordered Breathing
Spinal Cord Injuries · Sleep Disordered Breathing
Primary: CO2 Reserve (Delta-PETCO2-AT) — -3.8; -2.0 mmHg — p=0.015
Phase 3 N=580 Effect of Intravenous Acetaminophen on Postoperative Opioid-related Complications
Postoperative Pain
Primary: Duration of Hypoxemia — 0.7; 1.1 min/h — p=0.29
Phase 3 N=1,220 A Bioequivalence Study Using Clinical Endpoint for Diclofenac Sodium Gel 1% in Osteoarthritis Knee"
Osteoarthritis, Knee
Primary: Mean Change in the Total WOMAC Pain Subscale Score — -4.3; -4.6 score on a scale
Phase 2 N=292 A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Change in HbA1c After 12 Weeks of Treatment — 0.24; -0.31; -0.44; -0.56 percentage of glycated hemoglobin — p=< 0.0001